Summary A series of tumour related markers have been examined in 179 patients receiving primary endocrine therapy for metastatic breast cancer. Significant correlations between therapeutic response (UICC criteria after 6 months of treatment) and appropriate alterations in serum concentrations of carcinoembryonic antigen, ferritin, c-reactive protein, orosomucoid and the erythrocyte sedimentation rate, have been observed when changes in these markers were examined only at high serum concentrations. By combining these five markers a 'therapeutic index' of response has been devised which can be employed at an early stage of treatment in more than 90% of patients, giving an overall sensitivity/specificity of 90%/78% for therapeutic response or disease stabilisation over a 6-month period. The design of an objective measurement of response, which is easy to perform, has the potential to replace the existing, largely subjective, UICC criteria for retrospective judgement of response, and may also be used to direct systemic endocrine therapy.
Many systemic treatments are now available for the palliation of disseminated breast cancer. In the absence of an immediate threat to life, endocrine therapy remains the initial treatment of choice, due to its relative lack of toxicity. An early and accurate assessment of response to endocrine therapy would be of value, in order to allow a timely alteration of treatment in unresponsive patients. At present, such a decision is based upon ill defined clinical criteria, although the International Union Against Cancer (UICC) have suggested guidelines for the retrospective judgement of response in clinical trials (Hayward et al., 1977) .
Previous reports have explored the role of tumour markers in an attempt to measure therapeutic response objectively throughout treatment (Chu & Nemoto, 1973; Steward et al., 1974; Borthwick et al., 1977; Tormey et al., 1977a, b; Haagenson et al., 1978; Lamerz et al., 1980; Haagenson et al., 1980; Lee, 1983; Krieger et al., 1983; Coombes et al., 1983; Campbell et al., 1983; Heim et al., 1984; Hortobagyi et al., 1984) . Few studies have examined the potential of a combination of markers recorded simultaneously, despite indications that this approach might prove rewarding (Coombes et al., 1977; Woo et al., 1978; Cowen et al., 1978; Cove et al., 1979; Caffier & Brandau, 1983) .
This study describes an assessment of response to endocrine therapy which employs a combination of five tumour markers, and compares this biochemically based assessment with that achieved using the accepted clinical criteria after 6 months of treatment. The majority of tumour markers for advanced breast cancer have lacked specificity for the determination of response, as they have been employed at low concentrations which are frequently found in tumour-free women. The present study attempts to correct this by utilising markers only when concentrations exceed predefined high levels (above the ninetieth centile for control populations).
Patients and methods
One hundred and seventy-nine patients who presented to our clinic over a 2-year period were studied. All had advanced recurrent breast cancer and all received endocrine therapy as initial treatment for overt metastases. Treatment was prescribed according to several protocols and consisted of tamoxifen (Nolvadex, 20 mg b.d.) or megestrol acetate (Megace, 160 mg b.d.) in post-menopausal patients, and oophorectomy or a luteinising hormone-releasing hormone agonist (Zoladex, ICI 118630) in premenopausal patient. Menopausal status was confirmed using luteinising hormone and follicle stimulating hormone levels in women who had previously undergone hysterectomy, or who presented within 5 years after natural cessation of menstruation.
The oestrogen receptor status (ER) of primary tumour tissue had been documented in 109 patients; 51% were ER positive (greater than 5 fmol mg-' cytosol protein). ER estimations were performed at the Tenovus Institute, Cardiff, using the dextran coated charcoal method (Nicholson et al., 1981) .
All patients were staged before treatment in an advanced breast cancer clinic. All but six patients had received no previous endocrine treatment for overt metastases. Additional symptomatic treatments were prescribed throughout the study which included systemic analgesics, steroids and/or bronchodilators for lung metastases, and radiotherapy for skin ulceration or localised bone pain. Patients unassessable to hormonal therapy by either the type of presenting disease or the addition of local treatments were not included in the study. Sixteen patients were excluded from analysis as sequential serum samples were not available because of early death. The patients studied, therefore, represented the great majority of those attending one unit over a 2-year period, who received endocrine therapy for assessable metastatic disease.
Initial staging included a full clinical examination, documentation of the Karnofsky performance status (Karnofsky & Burchenal, 1948) and accurate measurement of local and regional disease, with photography when considered helpful for later evaluation of response. Radiological assessment consisted of lateral and antero-posterior views of the skull, chest, dorso-lumbar spine, pelvis and upper femora (limited skeletal survey). Painful sites of disease at other locations were X-rayed when clinically indicated. Isotope bone, liver and brain scans were requested only if clinically indicated.
Haematological assessment consisted of measurement of a full blood count, urea and electrolytes, serum calcium and albumin, the erythrocyte sedimentation rate and liver function tests (gamma-glutamyl transaminase, alanine transferase, alkaline phosphatase and bilirubin). In addition, several other 'tumour related markers' were assessed sequentially throughout active treatment (Table I) . These included two oncofetal proteins, serum carcinoembryonic antigen (CEA) and ferritin; two acute phase proteins, c-reactive protein (CRP) and orosomucoid; and the hormone beta human chorionic gonadotrophin (B-HCG). Calcium excretion (CAE) and the hydroxyproline creatinine ratio (OHP/CR) were (British Breast Group, 1974; Hayward et al., 1977 Assay techniques Routine biochemical and haematological parameters were measured using standard techniques.
CEA was measured using a monoclonal radiometric assay (Tandem-R CEA, kindly provided by Hybritech UK Ltd). The intra-and inter-assay coefficients of variation were 4.6-7.6% and 6.9-7.2%, respectively.
Serum concentrations of ferritin were measured using a solid phase, two site radioimmunoassay. Standards were prepared in ferritin free serum and calibrated against a WHO ferritin reference preparation. Standards covered the range of 0-1000 fig 1-'. The estimated intra-and inter-assay coefficients of variation, over the working range, were 3.7-5.9% and 4.6-6.0%, respectively.
Concentrations of the beta subunit of human chorionic gonadotrophin were measured by radioimmunoassay using an antiserum raised in rabbit against B-HCG. Standards were calibrated against the First International Reference Preparation (kindly provided by the National Institute of Biological Standards and Control, London) and were prepared to cover the range 0-640 IU 1'. The intra-and inter-assay coefficients of variation were 4.7-6.1% and 5.4 -8.8%, respectively.
Serum concentrations of CRP were measured using a turbidometric technique on a centrifugal fast analyser (Centrifichem Roche). Changes in optical density were monitored, using an on-line computer which calculated CRP concentrations (O'Callaghan et al., 1984) .
Orosomucoid was measured by immuno-turbimetry using a centrifugal fast analyser (Centrifichem 400). Standards were prepared from a commercially available serum (Behring Standard Human Serum, ORDT 06/07). Between batch precision for the assay was 7% at a concentration of 0.65 g 1-'.
Urinary OHP was estimated in duplicate using Hypronosticon Kits (Organon).
Analysis of results
Pre-treatment concentrations of each tumour marker were compared in individual patients with values recorded after 1-2, 3-4 and 5-7 months of treatment.
For each marker the correlation between alterations in concentration and clinical assessments of response was examined only in patients who presented with, or developed concentrations exceeding predefined levels; the proportion of patients that this represented for each marker is shown in the results. The object of this was to examine markers in each individual only when concentrations were well above those found in the majority of women without advanced disease; concentrations above this level may then be assumed to be due to the tumour. Such concentrations were seen in only 2-8% of women in the control groups. The 'cut-off' chosen for analysis also depended upon the shape of the distribution plots for each marker.
Patients maintaining concentrations within the 'normal' range have been considered unassessable for the marker in question. Above this level concentrations were classified as increasing or decreasing when they altered by more than 10% during treatment.
For statistical analysis patients with rising marker concentrations were combined with those in whom concentrations remained stable. Patients with no change in clinical disease status over 6 months, were combined with those showing objective response. Statistical significance was assessed using the x2 test with Yates' correction.
Finally, results of five markers were combined to form a 'therapeutic index', in order to improve the discrimination of response after 3-4 months of treatment.
Results
Patient details and therapeutic response One hundred and six patients presented with bone or lung metastases alone (n = 69 and n = 37, respectively). Thirty-eight presented with both bone and lung metastases, and 35 presented with other sites of visceral involvement (mainly hepatic). Twenty-three per cent of patients (41/179) were found to be premenopausal at the presentation of advanced disease.
The overall response rate was 26% (n = 47) using UICC criteria after 6 months. In 17% (n = 31) disease remained static for 6 months and in 56% (n = 101) disease progressed. Disease either responded or remained static in 64% (36/56) of ER positive patients and in 26% (14/53) of ER negative patients.
Correlation between therapeutic response and alterations in individual marker concentrations In only five markers did appropriate alterations in concentration correlate with UICC response to a degree that could be usefully employed in clinical practice (Table II) . For the remaining markers the correlation was weak and these latter results are not discussed further in this report.
In total, 579 serum samples were obtained for the analysis of tumour markers in patients with stage IV disease. These included 179 samples obtained immediately before treatment, 132 obtained after I or 2 months (from 128 patients), 131 after 3 or 4 months (from 128 patients) and 137 obtained after 5-7 months of treatment (from 114 patients).
Only the first recorded assay result has been considered for analysis when these were duplicated in individual patients during a single interval of treatment. Individual results for the five markers, recorded simultaneously on the same serum sample, were unavailable on several occasions; four pretreatment results and 10 follow-up results were not available for ESR, three follow-up results for CRP, and one for both orosomucoid and ferritin.
For each marker, the pre-treatment concentration in stage IV disease was compared with that found both in disease-free women attending a diagnostic breast clinic and in a series of patients presenting with stage III disease, in order to establish upper limits of normal. One hundred and twenty-eight stage IV patients had CEA concentrations measured before and after 1 or 2 months of treatment. Sixty-three (49% of the total) were assessable employing a CEA concentration in excess of 6 ng ml-'. One hundred and twenty-eight patients had CEA measurements repeated after 3 or 4 months of treatment, 71 (55%) were biochemically assessable as above. After 5 -7 months of treatment, 65 of 114 patients (57%) wre biochemically assessable. A highly significant association was found between the clinical assessment of response after 6 months, and changes in tumour marker concentration (above 6 ng ml-') during all three periods of treatment (Table II: stage IV disease have been examined only above 220 1g 1-'. One hundred and twenty-eight patients had ferritin levels recorded before and after 1 or 2 months of treatment. Fifty (39% of the total) were assessable using concentrations above 220 ptg ml-'. In one hundred and twenty-seven patients ferritin was measured before and after 3 or 4 months of treatment; 49 (39%) were biochemically assessable as above. In 114 patients ferritin was measured before and after 5-7 months of treatment, 48 (42%) were biochemically assessable.
Again, during each interval of treatment, a highly significant association existed between alterations in serum ferritin (above 220 pg ml-') and clinical assessments of response after 6 months (Table II: One hundred and twenty-seven patients with distant metastases had CRP concentrations measured before and after one or two months of treatment, of whom 70 patients (55% of the total) were assessable employing CRP concentrations in excess of 10 mg 1-'. One hundred and twenty-six patients had CRP concentrations measured before and after 3 or 4 months of treatment, 73 (58%) were assessable as above. In 114 patients CRP was measured before and after 5-7 months of treatment, 67 (59%) were biochemically assessable.
A highly significant association existed between therapeutic response (UICC) and alterations in CRP concentration during the three time intervals of treatment (Table II: months of treatment, 73 (58%) were assessable as above. In 114 patients CRP was measured before and after 5-7 months of treatment, 67 (59%) were biochemically assessable. A highly significant association existed between alterations in marker concentrations during each interval of treatment, and therapeutic response assessed using UICC criteria after six months (Table II (Figure 5) . Alterations in the ESR have been examined only above 20mmh-'.
One hundred and twenty-one stage IV patients had ESR measurements before and after 1 or 2 months of treatment. Ninety-one (75% of the total) were assessable employing an ESR of greater than 20mmh-'. One hundred and twelve patients had the ESR measured before and after 3 or 4 months of treatment, 97 (87%) were assessable. In 111 patients the ESR was measured before and after 5-7 months of treatment, 91 (82%) were assessable employing an ESR greater than 20 mm h-'.
Again, a highly significant association existed between alterations in the ESR during each interval of treatment and therapeutic response assessed after 6 months using UICC criteria (Table II: Combining markers to assess therapeutic response after 3-4 months of treatment From the results of individuals tumour markers it can be seen that the accuracy with which each marker was able to assess response, was highest during the 3-4 month interval of treatment.
In 127 patients the results of all five markers were available during this interval of treatment. Patients were considered biochemically unassessable when the concentrations of all five markers remained below the minimum levels adopted for analysis. This occurred in 10 patients (8% of the total). Of the remaining 117 biochemically assessable patients, 37 responded to treatment (UICC criteria), in 20 disease remained static for 6 months and in 60 disease progressed.
A 'therapeutic index' has been devised by allocating points according to a rise or a fall in each marker concentration above defined levels, as shown in Table III. Several factors were taken into consideration when constructing the index and different weighting was applied to appropriate alterations in each marker. Progressing disease was associated with high but stable marker concentrations (score + 1). However, high, stable marker concentrations did not detect disease progression as accurately as increasing marker concentrations (score + 2). The predictive value for disease progression of increasing concentrations of ferritin, the ESR and acute phase proteins (score + 2) was higher than the predictive value for non-progressing disease of falling concentrations (score -1). Finally, appropriate alterations in CEA were equally effective to confirm progressing and nonprogressing disease (score + 2 and -2, respectively).
When all five markers increased in concentration by more than 10%, a maximum index score of + 10 was achieved. Conversely, when all five markers were abnormal at presentation and decreased by more than 10%, a minimum index score of -6 was achieved.
The distribution of index scores at 3-4 months is shown after subgrouping patients according to UICC assessments of response at 6 months ( Figure 6 ). By employing a 'cut-off' lying *0 S... between index scores of 0 and + 1, the sensitivity that a low index score has for objective response (or disease stabilisation for 6 months) is 89.5% (51/57), with a specificity of 78% (47/60) (Table IV , group A; Figure 7 ). When patients with 'marked biochemical change' are considered separately, (index scores greater than + 2 or less than -2), the sensitivity for response/stasis increases to 92% (34/37) with a specificity of 100% (38/38) (Table IV , group B; Figure  8 ). Seventy-five patients (59% of the total) developed 'marked biochemical' responses to treatment.
Discussion
Significant advances have been made in the treatment of malignant diseases where specific markers are able to monitor tumour burden. Two examples are the use of B-HCG assays in choriocarcinoma (Begent & Bagshaw, 1982) and measurements of B-HCG and alpha fetoprotein in patients receiving treatment for testicular teratoma (Lange et al., 1976; Schultz et al., 1978; Lange, 1982) . These advances are dependent in part upon the ability to assess changes in tumour bulk at an early stage, which allows appropriate alteration of treatment.
This work seeks a marker of tumour burden for advanced breast cancer so that similar priniciples can be applied. A single marker with the desired specificity for response has not been found, even when each marker was examined at high serum concentrations. However, we have found that a combination of five markers (at high serum concentration) is able accurately to reflect therapeutic response of 6 months' duration. The five assays are easily performed, and their combination is able to discriminate between response groups at a relatively early stage of treatment.
Each marker has been considered only at high serum (Howell et al., 1984; Williams et al., 1986 
